The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Biomarkers for the early diagnosis of hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is generally poor, the 5-year survival rate is > 70% if patients are diagnosed at an early stage. However, early diagnosis of HCC is complicated by the coexistence of inflammation and cirrhosis. Thus, novel biomarkers for the early diagnosis of HCC are required. Currently, the diagnosis of HCC without pathological correlation is achieved by analyzing serum α-fetoprotein levels combined with imaging techniques. Advances in genomics and proteomics platforms and biomarker assay techniques over the last decade have resulted in the identification of numerous novel biomarkers and have improved the diagnosis of HCC. The most promising biomarkers, such as glypican-3, osteopontin, Golgi protein-73 and nucleic acids including microRNAs, are most likely to become clinically validated in the near future. These biomarkers are not only useful for early diagnosis of HCC, but also provide insight into the mechanisms driving oncogenesis. In addition, such molecular insight creates the basis for the development of potentially more effective treatment strategies. In this article, we provide an overview of the biomarkers that are currently used for the early diagnosis of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Comparison osteopontin vs AFP for the diagnosis of HCC: A meta-analysis
Wan, H., Xu, H., Gu, Y., Wang, H., Xu, W., & Zu, M. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.06.008 · Cited by 80
RetractedXu, W., Guo, B.-L., Han, Y.-G., Shi, L., & Ma, W. (2014) · Tumor Biology · doi:10.1007/s13277-014-2506-8 · Cited by 34
RetractedSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Nordberg, J., & Arnér, E. S. J. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00724-9 · Cited by 2,662
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T., & Shimotohno, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209283 · Cited by 1,147
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., Reddy, K. R., Harnois, D., Llovet, J. M., Normolle, D., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.005 · Cited by 745
Osteopontin: role in cell signaling and cancer progression
Rangaswami, H., Bulbule, A., & Kundu, G. C. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.12.005 · Cited by 735
Trevisani, F., D'Intino, P. E., Morselli-Labate, A. M., Mazzella, G., Accogli, E., Caraceni, P., Domenicali, M., De Notariis, S., Roda, E., & Bernardi, M. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00053-2 · Cited by 731
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
Zhou, J., Yu, L., Gao, X., Hu, J., Wang, J., Dai, Z., Wang, J.-F., Zhang, Z., Lu, S., Huang, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2697 · Cited by 635
Lok, A. S., Sterling, R. K., Everhart, J. E., Wright, E. C., Hoefs, J. C., Di Bisceglie, A. M., Morgan, T. R., Kim, H., Lee, W. M., Bonkovsky, H. L., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.031 · Cited by 558
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein
Sato, Y., Nakata, K., Kato, Y., Shima, M., Ishii, N., Koji, T., Taketa, K., Endo, Y., & Nagataki, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282502 · Cited by 439
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00908-2 · Cited by 430
Gupta, S., Bent, S., & Kohlwes, J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-1-200307010-00012 · Cited by 420
Muramatsu, T. (2002) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a003231 · Cited by 405
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
Marrero, J. A., Romano, P. R., Nikolaeva, O., Steel, L., Mehta, A., Fimmel, C. J., Comunale, M. A., D'Amelio, A., Lok, A. S., & Block, T. M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.028 · Cited by 364
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma
Tomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Tanemura, M., Tomokuni, A., Takemasa, I., Umeshita, K., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.026 · Cited by 361
AFP-L3: a new generation of tumor marker for hepatocellular carcinoma
Li, D., Mallory, T., & Satomura, S. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00644-1 · Cited by 358
Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein
&NA; (1994) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-199412000-00009 · Cited by 356
Poté, N., Cauchy, F., Albuquerque, M., Voitot, H., Belghiti, J., Castera, L., Puy, H., Bedossa, P., & Paradis, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.005 · Cited by 328
Identification of Osteopontin as a Novel Marker for Early Hepatocellular Carcinoma
Shang, S., Plymoth, A., Ge, S., Feng, Z., Rosen, H. R., Sangrajrang, S., Hainaut, P., Marrero, J. A., & Beretta, L. (2012) · Hepatology · doi:10.1002/hep.24703 · Cited by 322
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302
Self-citationThe Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families
Murakami, Y., Toyoda, H., Tanaka, M., Kuroda, M., Harada, Y., Matsuda, F., Tajima, A., Kosaka, N., Ochiya, T., & Shimotohno, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016081 · Cited by 282
Libbrecht, L., Severi, T., Cassiman, D., Borght, S. V., Pirenne, J., Nevens, F., Verslype, C., Pelt, J. V., & Roskams, T. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213323.97294.9a · Cited by 270
Mizejewski, G. J. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122600503 · Cited by 269
Micromarkers: miRNAs in cancer diagnosis and prognosis
Ferracin, M., Veronese, A., & Negrini, M. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.11 · Cited by 266
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma
Mao, Y., Yang, H., Xu, H., Lu, X., Sang, X., Du, S., Zhao, H., Chen, W., Xu, Y., Chi, T., et al. (2010) · Gut · doi:10.1136/gut.2010.214916 · Cited by 266
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Debruyne, E. N., & Delanghe, J. R. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.05.010 · Cited by 236
The Role of Annexin A2 in Tumorigenesis and Cancer Progression
Lokman, N. A., Ween, M. P., Oehler, M. K., & Ricciardelli, C. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0064-9 · Cited by 230
AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Rankin, E. B., Fuh, K. C., Taylor, T. E., Krieg, A. J., Musser, M., Yuan, J., Wei, K., Kuo, C. J., Longacre, T. A., & Giaccia, A. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1267 · Cited by 229
Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease
Kladney, R. D., Cui, X., Bulla, G. A., Brunt, E. M., & Fimmel, C. J. (2002) · Hepatology · doi:10.1053/jhep.2002.32525 · Cited by 227
Shiozawa, Y., Havens, A. M., Jung, Y., Ziegler, A. M., Pedersen, E. A., Wang, J., Wang, J., Lu, G., Roodman, G. D., Loberg, R. D., et al. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21835 · Cited by 226
Liu, A. M., Yao, T.-J., Wang, W., Wong, K.-F., Lee, N. P., Fan, S. T., Poon, R. T. P., Gao, C., & Luk, J. M. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000825 · Cited by 226
The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy
Waldmann, T. A., & McIntire, K. R. (1974) · Cancer · doi:10.1002/1097-0142(197410)34:8+<1510::aid-cncr2820340824>3.0.co;2-y · Cited by 225
Raffel, J., Bhattacharyya, A. K., Gallegos, A., Cui, H., Einspahr, J. G., Alberts, D. S., & Powis, G. (2003) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(03)00068-4 · Cited by 219
Marquardt, J. U., Galle, P. R., & Teufel, A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.007 · Cited by 195
Zhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., Ohishi, N., Ohtomo, T., & Philip, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2616 · Cited by 193
Kakolyris, S., Giatromanolaki, A. N., Koukourakis, M. I., Powis, G., Souglakos, J., Sivridis, E., Georgoulias, V., Gatter, K. C., & Harris, A. L. (2001) · PubMed · Cited by 185
Song, X., Wang, H., Logsdon, C. D., Rashid, A., Fleming, J. B., Abbruzzese, J. L., Gomez, H. F., Evans, D. B., & Wang, H. (2010) · Cancer · doi:10.1002/cncr.25483 · Cited by 174
Kawashima, R., Mochida, S., Matsui, A., YouLuTuZ, Y., Ishikawa, K., Toshima, K., Yamanobe, F., Inao, M., Ikeda, H., Ohno, A., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0372 · Cited by 148
Volk, M. L., Hernandez, J. C., Su, G. L., Lok, A. S.-F., & Marrero, J. A. (2007) · Cancer Biomarkers · doi:10.3233/cbm-2007-3202 · Cited by 147
Osteopontin: An Effector and an Effect of Tumor Metastasis
Shevde, L. A., Das, S., Clark, D., & Samant, R. S. (2010) · Current Molecular Medicine · doi:10.2174/156652410791065381 · Cited by 141
Leerapun, A., Suravarapu, S. V., Bida, J. P., Clark, R. J., Sanders, E. L., Mettler, T. A., Stadheim, L. M., Aderca, I., Moser, C. D., Nagorney, D. M., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.005 · Cited by 138
Diaz, V. M., Hurtado, M., Thomson, T. M., Reventós, J., & Paciucci, R. (2004) · Gut · doi:10.1136/gut.2003.026831 · Cited by 135
Han, Z., Chen, H., Fan, J., Wu, J., Tang, H., & Peng, Z. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1076-z · Cited by 121
Tressler, R., Updyke, T. V., Yeatman, T. J., & Nicolson, G. L. (1993) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240530311 · Cited by 120
Dunne, P. D., McArt, D. G., Blayney, J. K., Kalimutho, M., Greer, S., Wang, T., Srivastava, S., Ong, C. W., Arthur, K., Loughrey, M. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1354 · Cited by 119
Zhao, P., Zhang, W., Wang, S., Yu, X., Tang, J., Huang, W., Li, Y., Cui, H., Guo, Y., Tavernier, J. H., et al. (2010) · Hepatology · doi:10.1002/hep.24592 · Cited by 116
Abdalla, M. A. K., & Haj-Ahmad, Y. (2012) · Journal of Cancer · doi:10.7150/jca.3.19 · Cited by 114
Aghoram, R., Cai, P., & Dickinson, J. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002799.pub2 · Cited by 106
Nakatsura, T., Komori, H., Kubo, T., Yoshitake, Y., Senju, S., Katagiri, T., Furukawa, Y., Ogawa, M., Nakamura, Y., & Nishimura, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1177 · Cited by 97
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis
Schütte, K. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v7.i2.139 · Cited by 93
Tatarinov, I. S. (1996) · PubMed · Cited by 91
The role of glypican-3 in the regulation of body size and cancer
Filmus, J., & Capurro, M. (2008) · Cell Cycle · doi:10.4161/cc.7.18.6672 · Cited by 90
MicroRNA functional network in pancreatic cancer: From biology to biomarkers of disease
Wang, J., & Sen, S. (2011) · Journal of Biosciences · doi:10.1007/s12038-011-9083-4 · Cited by 89
Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma
Sun, Y., Gao, G.-Z., Cai, J., Wang, Y., Qu, X., He, L., Liu, F., Zhang, Y., Kaixuan, L., Ma, S., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs372 · Cited by 88
Jia, X., Liu, J., Gao, Y., Huang, Y. L., & Zhi, D. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.002 · Cited by 81
Early Hepatocellular Carcinoma: Pathology, Imaging, and Therapy
Takayama, T., Makuuchi, M., Kojiro, M., Lauwers, G. Y., Adams, R. B., Wilson, S. R., Jang, H., Charnsangavej, C., & Taouli, B. A. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9685-0 · Cited by 80
Shi, M., Chen, M.-S., Sekar, K., Tan, C., Ooi, L. L., & Hui, K. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.026 · Cited by 80
Squamous cell carcinoma antigen in human liver carcinogenesis
Guido, M., Roskams, T., Pontisso, P., Fassan, M., Thung, S. N., Giacomelli, L., Sergio, A., Farinati, F., Cillo, U., & Rugge, M. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.051383 · Cited by 80
Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma
Makarem, M. A. A. E., Aleem, A. A., Ali, A. I., Saber, R. A., Shatat, M., Rahem, D. A., & Sayed, D. M. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31541-8 · Cited by 75
Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma
Li, J., Cheng, Z., Liu, Y., Yan, Z., Wang, K., Wu, D., Wan, X., Xia, Y., Lau, W. Y., Wu, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3314 · Cited by 69
Motomura, Y., Senju, S., Nakatsura, T., Matsuyoshi, H., Hirata, S., Monji, M., Komori, H., Fukuma, D., Baba, H., & Nishimura, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2090 · Cited by 68
RADIOIMMUNOASSAY OF ALPHA-FETOPROTEIN IN HUMAN PLASMA
Chayvialle, J., & Ganguli, P. C. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91676-0 · Cited by 64
The Value of Serum Midkine Level in Diagnosis of Hepatocellular Carcinoma
Shaheen, K. Y., Abdelmageed, A. I., Safwat, E., & Al-Breedy, A. M. (2015) · International Journal of Hepatology · doi:10.1155/2015/146389 · Cited by 62
Axl receptor tyrosine kinase expression in breast cancer
D’Alfonso, T. M., Hannah, J., Chen, Z., Liu, Y., Zhou, P., & Shin, S. J. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-202161 · Cited by 62
Song (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000290 · Cited by 55
Annexin A2 recognises a specific region in the 3′-UTR of its cognate messenger RNA
Hollås, H., Aukrust, I., Grimmer, S., Strand, E., Flatmark, T., & Vedeler, A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.08.043 · Cited by 53
Reichl, P., Fang, M., Starlinger, P. P., Staufer, K., Nenutil, R., Müller, P., Greplová, K., Valík, D., Dooley, S., Brostjan, C., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29394 · Cited by 52
Hung, C., Liu, H.-H., Liu, J., Yeh, C., Chang, T., Wu, C., Ho, Y., Wei, P., & Chang, Y. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2482-4 · Cited by 52
Lomholt, A. F., Christensen, I. J., Høyer‐Hansen, G., et al. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.491086 · Cited by 52
Izumi, N. (2010) · Oncology · doi:10.1159/000315234 · Cited by 46
Nakatsura (2010) · Oncology Reports · doi:10.3892/or_00000888 · Cited by 46
Pinato, D. J., Mauri, F. A., Lloyd, T., Vaira, V., Casadio, C., Boldorini, R. L., & Sharma, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.9 · Cited by 44
Ido, A. (2011) · Oncology Reports · doi:10.3892/or.2011.1425 · Cited by 38
Cited by
Advances in the Early Diagnosis of Hepatocellular Carcinoma
Wang, W., & Wei, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.014 · Cited by 492
Metadata
- Authors
- Tsuchiya, N.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 21
- Issue
- 37
- Pages
- 10573
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W1864967712
- Cited by
- 569
- References
- 82
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.